Skip to main content

Canada University of Manitoba cuts ties with Ebola vaccine researcher pending RCMP investigation

The University of Manitoba says it has cut ties with an Ebola vaccine researcher pending the results of an RCMP investigation.

A spokesperson said the school has ended the non-salaried adjunct appointments of Dr. Xiangguo Qiu and her husband Keding Cheng.

Qiu, a renowned virologist who received her original medical training in China, helped develop a vaccine for the Ebola virus at the National Microbiology Laboratory in Winnipeg.

Story continues below advertisement

Cheng also worked at the lab as a researcher.

The Canadian Press has been unable to reach Qiu or Cheng for comment.

The Public Health Agency of Canada said on Monday that it was taking steps to address an “administrative matter” at the lab.

The agency said in a statement that it alerted the RCMP of a possible policy breach on May 24, adding that no employee of the lab is “under arrest or confined to their home.”

The laboratory is Canada’s highest-security infectious disease research facility dealing with deadly contagious germs.

The Public Health Agency said there is no risk to the public and work at the lab continues.

The RCMP in Manitoba have confirmed they received a referral from the health agency, but have not confirmed whether Qui or Cheng is being investigated.

Story continues below advertisement

In an English transcription posted on the Chinese foreign ministry’s website, spokesperson Geng Shuang said Monday that the Chinese Embassy in Canada has not received any notification that Chinese citizens were involved in the investigation.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter